AIB1 蛋白表达作为乳腺癌的预后因素。
Expression of AIB1 protein as a prognostic factor in breast cancer.
机构信息
Department of Hospital Pathology, College of Medicine, The Catholic University of Korea, 505 Banpo-dong, Seocho-Gu, Seoul 137-701, Korea.
出版信息
World J Surg Oncol. 2011 Oct 29;9:139. doi: 10.1186/1477-7819-9-139.
BACKGROUND
AIB1 (amplified in breast cancer I) is a member of the p160 steroid receptor coactivator family. AIB1 is frequently overexpressed in breast cancer and has functions that promote oncogenesis that are independent of estrogen receptor (ER) coactivation. We investigated prognostic significance of AIB1 and relationship between AIB1 and ER, progesterone receptor (PR), androgen receptor (AR), DAX-1, and HER2.
METHODS
RNA in situ hybridization (ISH) and immunohistochemical (IHC) staining for AIB1, IHC staining for ER and the progesterone receptor (PR) and IHC staining and silver in situ hybridization (SISH) for HER2 were performed for 185 breast cancer cases.
RESULTS
A high level of expression of AIB1 mRNA was observed in 60.0% of tumors. IHC analysis detected AIB1 positivity in 47.3% of tumors, which did not correlate with AIB1 mRNA expression (p = 0.24, r = 0.10). AIB1 protein expression correlated with AR and DAX-1 expression (p = 0.01, r = 0.22 and p = 0.02, r = 0.21, respectively) but not with ER or PR expression (p = 0.14, r = -0.13 and p = 0.16, r = -0.12, respectively). AIB1 protein expression correlated with the amplification of the HER2 gene (p = 0.03, r = 0.19). In contrast to AIB1 protein expression, AIB1 mRNA expression did not correlate with AR, DAX-1, ER, and PR expression, and the amplification of the HER2 gene (p > 0.05 for all).There were trends that strong AIB1 protein expression correlated with poorer disease free survival (p = 0.07). Strong AIB1 protein expression correlated with poorer overall survival (p = 0.04). Among the ER-negative subgroup, strong AIB1 protein expression correlated with poorer disease free survival and overall survival (p = 0.01 and p < 0.01, respectively).
CONCLUSIONS
Strong AIB1 protein expression was poor prognostic factor in breast cancer, especially in ER-negative breast cancers. Further investigation is essential to determine whether AIB1 might be effective therapeutic targets for ER-negative breast cancers.
背景
AIB1（乳腺癌 I 扩增）是 p160 甾体受体共激活因子家族的成员。AIB1 在乳腺癌中常过度表达，具有促进肿瘤发生的功能，且不依赖于雌激素受体（ER）的共激活。我们研究了 AIB1 的预后意义以及与 ER、孕激素受体（PR）、雄激素受体（AR）、DAX-1 和 HER2 之间的关系。
方法
对 185 例乳腺癌病例进行 AIB1 的 RNA 原位杂交（ISH）和免疫组织化学（IHC）染色、ER 和孕激素受体（PR）的 IHC 染色以及 HER2 的银原位杂交（SISH）。
结果
在 60.0%的肿瘤中观察到 AIB1 mRNA 高表达。IHC 分析检测到 47.3%的肿瘤存在 AIB1 阳性，与 AIB1 mRNA 表达无相关性（p = 0.24，r = 0.10）。AIB1 蛋白表达与 AR 和 DAX-1 表达相关（p = 0.01，r = 0.22 和 p = 0.02，r = 0.21），但与 ER 或 PR 表达无关（p = 0.14，r = -0.13 和 p = 0.16，r = -0.12）。AIB1 蛋白表达与 HER2 基因的扩增相关（p = 0.03，r = 0.19）。与 AIB1 蛋白表达相反，AIB1 mRNA 表达与 AR、DAX-1、ER 和 PR 表达以及 HER2 基因的扩增均无相关性（p > 0.05）。有趋势表明，AIB1 蛋白强表达与无病生存期较差相关（p = 0.07）。AIB1 蛋白强表达与总生存期较差相关（p = 0.04）。在 ER 阴性亚组中，AIB1 蛋白强表达与无病生存期和总生存期较差相关（p = 0.01 和 p < 0.01）。
结论
AIB1 蛋白强表达是乳腺癌的预后不良因素，尤其是在 ER 阴性乳腺癌中。需要进一步研究以确定 AIB1 是否可能成为 ER 阴性乳腺癌的有效治疗靶点。
Zotero 插件